US biotech funding continues to dramatically outpace Europe on all fronts—public and private, product and platform, large and small. No surprise there: most of Europe's biotechs are far less mature than their US counterparts, Europe has fewer specialist investors, and general risk aversion means there's barely any generalist investor interest in the sector.
But while public biotech funding in the US in 2003—at over $11 billion according to Windhover's Strategic Intelligence Systems Databases—outpaced...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?